Cala Trio™ is the first non-invasive targeted therapy developed for the treatment of Parkinson's Disease by Cala Health, Inc. It lowers the risk of hand tremors in adults who are living with Essential Tremor (ET).
Cala Trio is a prescribed therapy in the US. It is provided through a simple, wrist-worn device, which has the ability to treat the unique tremor symptoms in patients.
Cala Trio™ is a simple, wrist-worn device like a watch. This particular device sends small electrical signals and stimulates tremor-associated nerve cells in the wrist to normalise their activity, reducing hand tremors, without the need for invasive brain surgery or medication.
The device used for two 40-minute sessions per day for three months would efficiently lower the severity of hand tremor in people with essential tremor.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation (BDD) for Cala Trio therapy to treat action tremors in adults with Parkinson’s disease (PD).
Hand tremor in patients living with Parkinson's disease generally occurs when the arms are at rest while sitting or walking. In addition, action tremor normally occurs while using arms to perform any activity or task and it is also expected that more than half of the patients report action tremor.